# Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

> **NCT06072573** · PHASE3 · UNKNOWN · sponsor: **Apurano Pharmaceuticals GmbH** · enrollment: 558 (estimated)

## Conditions studied

- Pain
- Pain Syndrome
- Pain, Chronic
- Chronic Pain
- Chronic Pain Syndrome
- Diabetes
- Diabetic Neuropathies
- Diabetic Polyneuropathy
- Peripheral Neuralgia
- Peripheral Neuropathy
- Peripheral Neuropathy With Type 2 Diabetis

## Interventions

- **DRUG:** Adezunap (AP707)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06072573
- **Lead sponsor:** Apurano Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-02
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 558 (ESTIMATED)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072573, "Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06072573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*